← All trials
NCT05538689
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Oct 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Sep 14, 2022
- Last posted
- Sep 23, 2022
- Enrollment
- 136
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ChicagoLead sponsor
- Myovant Sciences GmbHCollaborator
- University of ChicagoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.